#ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayer

Roivant Sciences said Tuesday its inhaled drug candidate has passed a mid-stage test in interstitial lung disease, surpassing Wall Street’s benchmarks for success. In the Phase 2 trial, mosliciguat met the primary endpoint of change ...